Your browser doesn't support javascript.
Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis.
Ordaya, Eloy E; Beam, Elena; Yao, Joseph D; Razonable, Raymund R; Vergidis, Paschalis.
  • Ordaya EE; Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Beam E; Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Yao JD; Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Razonable RR; Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Vergidis P; Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Open Forum Infect Dis ; 9(7): ofac283, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1948427
ABSTRACT
Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the need to maintain additional measures to prevent COVID-19 during periods of high severe acute respiratory syndrome coronavirus 2 transmission.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: Open Forum Infect Dis Year: 2022 Document Type: Article Affiliation country: Ofid

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: Open Forum Infect Dis Year: 2022 Document Type: Article Affiliation country: Ofid